Background and aims The prognostic value of the degree of apoptosis in colorectal cancer is controversial. This study evaluates the putative clinical usefulness of measuring caspase-3 activity as a prognostic factor in colonic cancer patients receiving 5-fluoracil adjuvant chemotherapy. Materials and methods We evaluated caspase-3-like protease activity in tumours and in normal colon tissue. Specimens were studied from 54 patients. Conclusion Low caspase-3 activity in the normal mucosa and tumour are independent prognostic factors of tumour recurrence in patients receiving adjuvant 5-fluoracil-based treatment in colon cancer, correlating with poor disease-free survival and higher recurrence rate.
Introduction
Colorectal cancer is a major cause of death in Western countries. Adjuvant chemotherapy, mainly based on fluoropyrimidine treatment, is a standard strategy when lymph node metastases are present. Some stage II (Dukes B) patients are at high risk of recurrence and are also treated. However, the benefit of adjuvant therapy is still limited; it improves 5-year survival by only 7-10%, and some patients show resistance to treatment and poor prognosis. As a result, there is growing interest in the search for biological markers of possible prognostic value.
Tissue homeostasis is achieved by a delicate balance between cell proliferation and death. In recent years, the contribution of resistance to apoptosis and tumourigenesis has become increasingly apparent. In colorectal cancer, it has been suggested that the adenoma-carcinoma transition is associated with resistance to apoptosis, although the evidence is controversial.
The search for novel biological markers predicting response to therapy is intense. The observation that resistance to apoptosis is a major contributor to resistance to either chemo-or radiotherapy has aroused strong interest in measuring apoptosis and evaluating its usefulness as a prognostic marker or as a predictor of response to therapy [1, 2, 3] . Several methods have been developed for its measurement, including light microscopic examination of haematoxylin-eosin-stained sections showing the morphological criteria defined by Kerr et al. [4] , Hoechst staining for chromatin condensation [5] , the Terminal transferase deoxyuridine triphosphate nick-end labelling (TUNEL) assay [6] and the annexin test [7] .
The potential predictive or prognostic value of the degree of apoptosis in colorectal cancer is controversial. Several studies have examined the prognostic value of the apoptotic index in tumour and normal tissue, producing conflicting results [8] . Recently, low levels of spontaneous apoptosis measured by the TUNEL assay and immunohistochemical staining of Bcl-2 were associated with resistance to neoadjuvant treatment in rectal cancer [9] . Low apoptotic levels have also been related to poor prognosis in colorectal cancer [10] . However, other studies reported an inverse relationship between apoptosis and prognosis in colorectal cancer [11, 12, 13] . These conflicting results may be attributed to differences in study design, patient selection criteria and the methods used to quantify apoptosis.
The measurement of final effectors of apoptosis such as caspase-3 has been proposed as a more sensitive alternative measure of the apoptosis process [14] . Caspase-3 is a proapoptotic protease, which induces intracellular processes leading to cell death. After activation of caspase-3 by a proteolytic cleavage, the cell is committed to programmed cell death. Caspase-3 activity has been used to quantify apoptosis in colon cancer. Its levels are higher in tumour than in healthy mucosa [15] . Nevertheless, we do not know whether these levels are due exclusively to alterations present in tumour cells or whether individual susceptibility also plays a role. In this regard, apoptosis has been related to over-expression of several repair genes, suggesting that the balance between cell death and proliferation may be critically affected by individual variability in these functions [15] .
The aim of the present study was to evaluate the putative clinical usefulness of measuring caspase-3 activity in tumours and corresponding normal tissue as a prognostic factor in colorectal cancer patients receiving 5-fluoracil (FU)-based adjuvant chemotherapy.
Materials and methods

Patient selection
From January 1996 to June 2000, a prospective study was carried out in all patients with a new diagnosis of colorectal cancer who were surgically resected at the Hospital Universitario de Bellvitge, Barcelona, Spain. To identify biomarkers of resistance to adjuvant chemotherapy, patients were stringently selected according to the following inclusion criteria: (a) tumour located in the colon, (b) elective radical surgery, i.e. resection margins clear of tumour, (c) 5-FU adjuvant therapy and (d) Dukes stage B2 with high-risk factors defined as invasion of adjacent organs, lymphatic or vascular infiltration or carcinoembryonic antigen [CEA]>5 and Dukes C. Fifty-four patients meeting these criteria were identified. Age, sex, tumour location, pre-operative CEA, tumour size, tumour differentiation, vascular invasion and lymphatic invasion were included in a prospective data base of all patients. Patients gave informed written consent to participate in the study and to have their biological specimens analysed.
Adjuvant chemotherapy
After surgery, all patients received adjuvant chemotherapy. In the first 2 years of the study, standard treatment was 5-FU 450 mg/m 2 bolus injection on days 1 to 5 and after 4 weeks once a week plus levamisole 50 mg three times a day (oral) on days 1 to 3 and 15 to 17 for 1 year. From 1998 onwards, 5-FU plus leucovorin (5-FU 425 mg/m 2 bolus injection on days 1 to 5 and leucovorin 20 mg/m 2 intravenously on days 1 to 5 every 28 days for 6 months) was administered.
Follow-up
Prospective active clinical follow-up was available for all patients. Median follow-up was 73 months. Events recorded included the development of local recurrence, distant metastases and death. Disease-free survival was calculated from the time of surgery until recurrence or last follow-up visit.
Caspase-3 activity measurements
Representative fragments of tumour and normal mucosa tissue (resection margins clear of tumour) were obtained in accordance with previously established protocols, and the samples were immediately frozen in liquid nitrogen for further analysis. Caspase-3-like activity was determined by measuring proteolytic cleavage of the specific substrate N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-AMC; Biomol, Plymouth Meeting, PA). Briefly, tissue was homogenated and sonicated in assay buffer (50 mmol/L hydroxyethyl piperazineethanesulfonic acid, 10% sucrose, 0.1% cholamidopropyl-dimethylammonioproanesulfonate , 5 mmol/L oxidized glutathione, 5 mmol/L dithiothreitol). We used 25 μg of protein of each sample and 12 μmol/L DEVD-AMC to perform the assay. The AMC released was quantified for 105 min at 37°C by fluorospectrophotometry using 380-nm excitation and measurement of 450-nm emission. Total protein concentration in homogenates was determined using a commercial kit from BioRad (Munich, Germany). Values of caspase-3 activity were expressed as units (pmols AMC mg protein
).
Statistical analysis
To analyse the influence of the different factors on tumour recurrence, a univariate analysis was performed using the Chi-squared test for qualitative variables and the MannWhitney test for non-parametric mean comparison. Variables included in this analysis were: age, sex, preoperative CEA, Dukes stage, vascular invasion, lymphatic invasion, tumour location, tumour differentiation, caspase-3 activity in normal mucosa and caspase-3 activity in tumour. To evaluate possible interactions between caspase-3 activity in normal mucosa or in the tumour with other potential prognostic factors, the relationship between variables was studied using the Chi-squared test for qualitative variables and the Mann-Whitney test for non-parametric mean comparison. Spearman's correlation coefficient was used. Paired data (normal tissue and tumour) were analysed by means of the Wilcoxon test.
Predictors that were significant in the univariate analysis and those with p<0.25 (screening criteria) were considered for multivariate analysis with Cox regression (stepwise regression). Variables significantly related to caspase-3 activity were also included. Caspase-3 activity in the tumour and normal mucosa were included in separate Cox regressions because of collinear incompatibility. Caspase-3 activity was considered as a continuous variable in Cox regression.
To analyse the probability of disease-free survival in relation to caspase-3 activity, the value was categorized using median values as the cutoff points. The median was selected because of the asymmetric distribution of the mean. The Kaplan-Meyer method and log-rank test were applied.
Odds ratios and 95% confidence intervals were estimated from the models. Statistical significance was considered when p<0.05.
Results
Fifty-four patients (28 men), median age 60.2 years, were included in the study. Thirty-two were Dukes stage C, and 22 were B2. The clinical characteristics of patients are shown in Table 1 .
Recurrence and survival
Sixteen patients (30%) developed tumour recurrence during the follow-up period. Thirteen of them died; the crude 3-and 5-year overall survival rates were 82 and 74%, respectively. The 5-year survival rate according to patients' demographics and tumour characteristics are shown in Table 2 . Table 3 shows the univariate study of prognostic factors of tumour recurrence. Variables showing a statistical significant relation with tumour recurrence were: age (p= 0.024), Dukes stage (p=0.021) and caspase-3 activity in normal mucosa (p=0.003).
Variables showing p<0.25 were: sex (p=0.094), caspase-3 activity in tumour (p=0.053) and lymphatic invasion (p=0.17).
Caspase-3 activity
Median values of caspase-3 activity of normal mucosa were 40.6 U (interquartile range [IQR]=22-103). In tumours, median values were more than double (88.1 U, IQR=54-159). The difference was statistically significant (p=0.001). Relation between caspase-3 activity and other prognostic factors Caspase-3 activity in the tumour was significantly higher in men (p=0.012) and in the group of patients without vascular invasion (p=0.036). In normal mucosa, higher caspase-3 activity correlated with CEA<5 serum levels before surgery (p=0.019). Results are shown in Table 4 .
Prognostic value of caspase-3 activity
Higher caspase-3 activity was associated with less tumour recurrence. The rate of recurrence was significantly higher when caspase-3 activity in normal tissue was below the median value (p=0.03; OR=5. Figure 2 shows the analysis of the probability of disease-free survival in relation to caspase-3 activity.
Multivariate study
Results are shown in (pmols AMC mg protein −1 min −1 ) that caspase-3 activity increased, the probability of tumour recurrence rose by between 1 and 3%.
Discussion
Apoptosis has been increasingly related to response to chemotherapy. In this study, we show that low activity in normal mucosa of caspase-3, a final mediator of apoptosis, is an independent prognostic factor in patients receiving adjuvant 5-FU-based treatment in colon cancer and correlates with poor disease-free survival and a higher rate of recurrence. These results strongly suggest that individual susceptibility to apoptosis may have an influence on response to treatment.
Resistance to apoptosis is a key characteristic of neoplastic cells, and response to chemotherapy is thought to be related to the capacity to restore the apoptotic programme in a given tumour cell [16, 17, 18] . Several methods have been used to measure apoptosis in tumours, including the TUNEL assay [6] and Iressa Survival Evaluation in Lung Cancer [19] . These methods have significant limitations because autolytic and apoptotic cells are assessed simultaneously and the conditions are difficult to standardize, leading to a high frequency of false-negative results. In this study, we used caspase-3 activity, which has been shown to correlate with TUNEL analyses and has the advantage of being more specific for irreversible apoptosis [14] . Caspase-3 activity is a final effector of the apoptotic programme. Being a late step in the apoptotic cascade, it is likely that its variations reflect the accumulated effect of small variations in a number of genes harbouring distinct functions such as deoxyribonucleic acid (DNA) damage sensors, cell cycle checkpoints, DNA repair and the apoptotic cascade itself, among others. Analytically, the determination of caspase-3 activity is a straightforward procedure, readily amenable to automation. However, its routine use in the clinical setting may be hampered by the need for fresh frozen tissue.
Although the sample size is limited, the study analyses a carefully selected, homogeneous, consecutive series of patients in a prospective study receiving chemotherapy treatment at a single institution with long follow-up. We Values of caspase-3 activity were expressed as units (pmols AMC mg protein −1 min −1 ). Degree of differentiation: W-M well-moderately, P poor Fig. 2 Kaplan-Meyer disease-free survival curves of colon cancer patients receiving 5-fluoracil adjuvant chemotherapy in relation to caspase-3 activity in tumour (cutoff point=88.1 U) and in normal mucosa (cutoff point=40.6 U) restricted the analysis to colon carcinomas so as to avoid interference with the impact of radiotherapy in rectal cancer. Because previous reports have observed lower apoptotic activity in more advanced stages of the disease [20] , we decided to include only Dukes B2 and C patients. Caspase-3 activity in normal mucosa and tumour tissue has shown a strong association with disease-free survival. The Cox multivariate analysis identified caspase-3 activity in the tumour and in the mucosa as independent risk factors of recurrence together with Dukes stage C tumour, age and male sex. In our study, the risk of recurrence was six times higher in patients with caspase-3 values below the mean in tumour tissue and five times higher in patients with caspase-3 values below the mean in normal mucosa. These data should be considered with some caution because of the small sample size and wide confidence intervals. Prospective studies with a larger number of patients are needed for a more accurate determination of the threshold above which the value of caspase-3 activity involves a risk of recurrence. What the study does show is that caspase-3 activity in the tumour and in the mucosa are important biological markers that should be taken into consideration in the evolution of patients with Dukes B2 or C colon cancer under chemotherapy.
There is an interesting relationship between caspase-3 activity and other biological tumour markers such as preoperative CEA, male sex and vascular invasion. This seems to suggest that apoptosis in tumour tissue and in healthy mucosa may be influenced and even modulated by constitutional factors such as sex. The association between caspase-3 activity and other known markers of poor tumour prognosis such as CEA>5 and vascular invasion suggest a relationship between apoptosis and the process of tumour growth, as other studies have noted [8, 11, 15] .
Caspase-3 activity in the tumour was higher than in the normal mucosa. Tumours are highly heterogeneous, and their proliferative activity is superior to that found in the corresponding normal mucosa. Their intrinsic genetic instability allows the continuous generation of novel subclones that may or may not be viable. The higher degree of apoptosis observed is probably related to the higher turnover found in tumours as a balance between hyper-proliferation and cell death secondary to the generation of non-viable clones because of mitotic failure, lack of oxygen or nutrients or other causes. The increase in apoptotic rate in tumours is in agreement with previous reports [18, 19] . Other reports have also shown that apoptotic indexes may be independent prognostic factors in tumours with no lymph node involvement [21] . However, to our knowledge, none of these studies measured caspase-3 activity in normal mucosa.
In conclusion, low caspase-3 activity in the normal mucosa and tumour are independent prognostic factors of tumour recurrence in patients receiving adjuvant 5-FUbased treatment in colon cancer, correlating with a poor disease-free survival and a higher recurrence rate. The simplicity of the test and the fact that caspase-3 activation is the final mediator/effector of the apoptotic programme make it a useful and attractive indicator in clinical practice, but larger prospective studies are needed to determine the specific role of apoptosis in the recurrence of Dukes stage B2 and C colon tumours after chemotherapy, as well as its value as a marker in daily clinical practice.
